PR Newswire
London, May 23
BLOCK LISTING SIX MONTHLY RETURN
May 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
| Name of applicant: | Shire plc | |||
| Name of scheme: | Shire Sharesave Scheme | |||
| Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
| Balance of unallotted securities under scheme(s) from previous return: | 184,611 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 17,079 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 167,532 | |||
| Name of applicant: | Shire plc | |||
| Name of scheme: | Shire Portfolio Share Plan | |||
| Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
| Balance of unallotted securities under scheme(s) from previous return: | 769,615 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 405,083 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 364,532 | |||
| Name of applicant: | Shire plc | |||
| Name of scheme: | Shire Employee Stock Purchase Plan | |||
| Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
| Balance of unallotted securities under scheme(s) from previous return: | 244,057 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 6,359 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 237,698 | |||
| Name of applicant: | Shire plc | |||
| Name of scheme: | Shire Long Term Incentive Plan 2015 | |||
| Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
| Balance of unallotted securities under scheme(s) from previous return: | 2,836,412 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 145,740 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 2,690,672 | |||
| Name of applicant: | Shire plc | |||
| Name of scheme: | Shire Global Employee Stock Purchase Plan | |||
| Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
| Balance of unallotted securities under scheme(s) from previous return: | 1,604,243 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 3,400 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,600,843 | |||
| Name of applicant: | Shire plc | |||
| Name of scheme: | Baxalta Exchange Awards | |||
| Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
| Balance of unallotted securities under scheme(s) from previous return: | 20,488,204 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 2,492,337 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 17,995,867 | |||
| Name of contact: | Sarah Rixon, Company Secretarial Assistant |
| Telephone number of contact: | 01256 894000 |
For further information please contact:
| Investor Relations | ||
| Ian Karp | ikarp@shire.com | +1 781 482 9018 |
| Robert Coates | rcoates@shire.com | +44 1256 894874 |
| Media | ||
| Lisa Adler | lisa.adler@shire.com | +1-617 588 8607 |
| Debbi Ford | debbi.ford@shire.com | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com
